Will it be an upside surprise? In-line? Or, below expectations? And, will there be a mention of the ENHANCE-era Cain v. Hassan pending settlement, if the board has met (and approved it) by then?
We shall see.
I'll try to live-blog the highlights -- look for word on how Merck's boceprevir (branded as Victrelis®) is doing against J&J/Vertex's telaprevir (branded as Incivek®) -- in the next gen Hep C cure wars. Here is the Merck site webcast link -- you'll need to sign in (with an email address). Look for it then, then:
. . . .Merck, known as MSD outside the United States and Canada, will hold its third-quarter 2011 sales and earnings conference call with institutional investors and analysts at 8 a.m. EDT on Friday, Oct. 28. During the call, Kenneth C. Frazier, president and chief executive officer, Peter N. Kellogg, executive vice president and chief financial officer, and Adam H. Schechter, president, Global Human Health, will provide an overview of Merck's financial performance for the quarter. . . .